Non-Small Cell Lung Carcinomas (NSCLC) account for around 85% of lung cancers and includes predominantly adenocarcinoma and squamous cell carcinoma. Depending on the patients’ medical status and stage of disease, treatment options include surgery, radiation therapy and chemotherapy. Although cytotoxic chemotherapy remains an important part of treatment, targeted therapies based on genetic alterations in the tumour are appropriate for selected cases. Identifying disease-causing variants in oncogenes associated with NSCLC can help determine which patients are more likely to benefit from a targeted therapy.
Rearrangements of the gene encoding anaplastic lymphoma kinase (ALK) have been linked to abnormal proliferation and NSCLC (most commonly adenocarcinoma). The most common ALK rearrangement in NSCLC is EML4-ALK, which arises from fusion between the 5’ end of the EML4 gene and the 3’ end of the ALK gene on chromosome 2p23. Patients with ALK rearrangements are younger than most patients with NSCLC. EML4-ALK rearrangements are also more common in adenocarcinomas of light or non-smokers. In addition, ALK gene rearrangements are rarely coincident with EGFR, HER2 or KRAS variants, indicating it is a distinct disease subtype.
Patients with ALK rearrangements may be considered for therapy targeting the activated receptor tyrosine kinase (TKI) that results from EML4-ALK and other ALK fusions.
Responses to anti-PD-1 and anti-PD-L1 agents are enhanced in patients whose tumors express high levels of PD-L1 compared with those expressing low or no tumor PD-L1. As such, reliable testing assays are required to inform treatment choices. Broad access to high-quality PD-L1 testing will help clinicians to identify the most appropriate treatment option for individual patients with NSCLC, including chemotherapy versus anti-PD-1/PD-L1, and single-agent anti-PD-1/PD-L1 versus combination immunotherapy regimens.
Current data indicate that PD-L1 expression predicts survival outcome in lung cancer patients treated with PD-1 antibodies.
The ROS1 gene makes a protein that is involved in sending signals in cells and in cell growth. Mutated forms of the ROS1 gene and protein have been found in some types of cancer, including non-small cell lung cancer (NSCLC), a type of brain cancer called glioblastoma multiforme, and cancers of the bile duct, ovary, stomach, colon, and rectum. The protein made by the ROS1 gene is a type of receptor tyrosine kinase.
Less than 2% of people with NSCLC have ROS1-positive advanced NSCLC. The ROS1 oncogene is thought to be found almost exclusively in non-squamous NSCLC, mainly in tumours with adenocarcinoma histology. In the absence of any targeted therapy until now, ROS1-positive advanced NSCLC is treated with cytotoxic chemotherapy that can cause unpleasant side effects. Crizotinib is now recommended for use within the Cancer Drugs Fund as an option for treating ROS1-positive advanced NSCLC in adults. ROS1 status should be tested upfront in all non-squamous NSCLC, testing for ROS1 status in all newly diagnosed nonsquamous NSCLC is recommended in line with testing for other types of tumour expression in NSCLC.
This one of the most frequently mutated genes in non-small cell lung cancer (NSCLC), resulting in constitutive activation of cellular signalling pathways that induce and sustain tumorigenesis. By testing for EGFR mutations, personalised treatment can be employed using established targeted kinase inhibitors to preferentially kill malignant cells. All non-small cell non-squamous lung cancers are reflex tested for EGFR mutation following reporting of the patient’s cytology or histology.
If you require advice on sample suitability please contact:
Dr M. Powari, Consultant Histopathologist, RDE
firstname.lastname@example.org or on 01392 402999
If you require a sample to be tested for the presence of ALK, PD-L1 or EGFR rearrangements please complete the ALK, PD-L1, EGFR & ROS1 testing request form
Specimen Labelling Procedure